These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9330414

  • 41. Short-Term Growth During Treatment with Inhaled Fluticasone Propionate/Formoterol, Fluticasone and Beclomethasone Treatment.
    Wolthers OD, Moore A, Mersmann S, Dissanayake S.
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):373-380. PubMed ID: 28510491
    [Abstract] [Full Text] [Related]

  • 42. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma.
    Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E.
    Arch Dis Child; 1993 Aug; 69(2):206-11. PubMed ID: 8215522
    [Abstract] [Full Text] [Related]

  • 43. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 44. Growth and adrenal suppression in asthmatic children on moderate to high doses of fluticasone propionate.
    Wong JY, Zacharin MR, Hocking N, Robinson PJ.
    J Paediatr Child Health; 2002 Feb; 38(1):59-62. PubMed ID: 11869402
    [Abstract] [Full Text] [Related]

  • 45. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
    Kerwin EM, Nathan RA, Meltzer EO, Ortega HG, Yancey SW, Schoaf L, Dorinsky PM.
    Respir Med; 2008 Apr; 102(4):495-504. PubMed ID: 18206361
    [Abstract] [Full Text] [Related]

  • 46. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1).
    Hoekx JC, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J.
    Eur Respir J; 1996 Nov; 9(11):2263-72. PubMed ID: 8947070
    [Abstract] [Full Text] [Related]

  • 47. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate.
    Eid N, Morton R, Olds B, Clark P, Sheikh S, Looney S.
    Pediatrics; 2002 Feb; 109(2):217-21. PubMed ID: 11826198
    [Abstract] [Full Text] [Related]

  • 48. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P.
    Pharmacoeconomics; 2004 Feb; 22(12):815-25. PubMed ID: 15294013
    [Abstract] [Full Text] [Related]

  • 49. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.
    Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C.
    J Pediatr; 2005 Aug; 147(2):213-20. PubMed ID: 16126052
    [Abstract] [Full Text] [Related]

  • 50. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
    Aubier M, Pieters WR, Schlösser NJ, Steinmetz KO.
    Respir Med; 1999 Dec; 93(12):876-84. PubMed ID: 10653049
    [Abstract] [Full Text] [Related]

  • 51. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate.
    Rojas RA, Paluga I, Goldfrad CH, Duggan MT, Barnes N.
    J Asthma; 2007 Dec; 44(6):437-41. PubMed ID: 17654129
    [Abstract] [Full Text] [Related]

  • 52. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma.
    Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, Brackel HJ, Gerrits GP, Hop WC, Duiverman EJ, COMBO Study Group.
    Am J Respir Crit Care Med; 2010 Nov 15; 182(10):1221-7. PubMed ID: 20622031
    [Abstract] [Full Text] [Related]

  • 53. Fluticasone propionate compared with theophylline for mild-to-moderate asthma.
    Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ.
    Ann Allergy Asthma Immunol; 1996 Aug 15; 77(2):112-8. PubMed ID: 8760776
    [Abstract] [Full Text] [Related]

  • 54. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
    Kupryś-Lipińska I, Tworek D, Vanderbist F, Bocheńska-Marciniak M, Kuna P.
    Pneumonol Alergol Pol; 2013 Aug 15; 81(6):527-36. PubMed ID: 24142782
    [Abstract] [Full Text] [Related]

  • 55. Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy.
    Kim KT, Ginchansky EJ, Friedman BF, Srebro S, Pepsin PJ, Edwards L, Stanford RH, Rickard K.
    Ann Allergy Asthma Immunol; 2000 Nov 15; 85(5):398-406. PubMed ID: 11101185
    [Abstract] [Full Text] [Related]

  • 56. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height.
    Visser MJ, Postma DS, Arends LR, de Vries TW, Duiverman EJ, Brand PL.
    Am J Respir Crit Care Med; 2001 Dec 01; 164(11):2073-7. PubMed ID: 11739137
    [Abstract] [Full Text] [Related]

  • 57. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS, Risebrough N, Li C, Corriveau D, Hawkins N, FitzGerald JM, Su Z.
    Respir Med; 2014 Sep 01; 108(9):1292-302. PubMed ID: 25175480
    [Abstract] [Full Text] [Related]

  • 58. [A multicenter, open-label, randomized comparison of suppressive effects on asthmatic inflammation of lower airways and improved effects on health-related QOL between HFA-BDP and fluticasone propionate].
    Ohbayashi H, Adachi M, Ichinose M, Ohta K, Kokubu F, Sano Y, Tamura G, Tohda Y, Hirata K, Yasuba H.
    Arerugi; 2007 Jun 01; 56(6):577-86. PubMed ID: 17615501
    [Abstract] [Full Text] [Related]

  • 59. Urinary fluticasone propionate-17beta-carboxylic acid to assess asthma therapy adherence.
    Hagan JB, Netzel BC, Matthews MR, Korpi-Steiner NL, Singh RJ.
    Allergy Asthma Proc; 2012 Jun 01; 33(4):e35-9. PubMed ID: 22856629
    [Abstract] [Full Text] [Related]

  • 60. Fluticasone propionate in asthma: a long term dose comparison study.
    Verona E, Petrov D, Cserhati E, Hofman J, Geppe N, Medley H, Hughes S.
    Arch Dis Child; 2003 Jun 01; 88(6):503-9. PubMed ID: 12765916
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.